T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

American Journal of Hematology
Jonathan CanaaniArnon Nagler

Abstract

Acute myeloid leukemia (AML) patients harboring the FLT3-ITD mutation are considered a high risk patient subset preferentially allocated for allogeneic stem cell transplantation in first remission. Whether FLT3-ITD retains a prognostic role in haploidentical stem cell transplantation (haplo-SCT) is unknown. To analyze the prognostic impact of FLT3-ITD in haplo-SCT, we performed a retrospective analysis of the multicenter registry of the acute leukemia working party of the European Society for Blood and Marrow Transplantation. We included all adult AML patients with known FLT3 status who underwent a first T-cell replete related haplo-HCT in first complete remission from 2005 to 2016. We evaluated 293 patients of whom 202 were FLT3wt and 91 were FLT3-ITD mutated. FLT3-ITD patients were more likely to be NPM1 mutated as well as be in the intermediate risk cytogenetic risk category. In multivariate analysis, patients with FLT3-ITD had comparable rates of relapse incidence [Hazard ratio (HR) = 1.34, confidence interval (CI) 95%, 0.67-2.7; P = .9] and leukemia-free survival (HR = 0.99, CI 95%, 0.62-1.57; P = .9) to those of FLT3wt patients. Overall survival, the incidence of nonrelapse mortality, and graft versus host disease-free/re...Continue Reading

References

Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia D BaldusGerhard Ehninger
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Feb 22, 2007·Blood·Martin BornhäuserUNKNOWN AML SHG 96 study group
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Sep 14, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yu WangXiao-Jun Huang
Feb 18, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Amy E DeZernMark Levis
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salut BrunetVanderson Rocha
Jul 7, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gaëlle LabouréStéphane Vigouroux
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 14, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellUNKNOWN National Comprehensive Cancer Network
Sep 13, 2014·Expert Review of Hematology·Ying-Jun ChangXiao-Jun Huang
Sep 30, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Antonio Di StasiStefan O Ciurea
Oct 14, 2014·Blood Reviews·Stefan O Ciurea, Ulas D Bayraktar
Aug 11, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailUNKNOWN American Society for Blood and Marrow Transplantation
Aug 26, 2015·Nature Reviews. Clinical Oncology·Christopher G KanakryLeo Luznik
Sep 10, 2015·Blood·Christoph SchmidUNKNOWN Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation
Nov 10, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A D HoUNKNOWN Study Alliance Leukemia (SAL)
Dec 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daisuke ArakiRoland B Walter
Jan 19, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rosy DabasJan Storek
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jan 21, 2017·Journal of Hematology & Oncology·Simona PiemonteseUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

❮ Previous
Next ❯

Citations

Dec 7, 2018·Hematology·Gregory W Roloff, Elizabeth A Griffiths
Feb 28, 2020·International Journal of Molecular Sciences·Stephen S Y Lam, Anskar Y H Leung
Nov 9, 2019·Therapeutic Advances in Hematology·Abdul Hamid BazarbachiAli Bazarbachi
Nov 15, 2018·Blood Advances·Gregory W Roloff, Elizabeth A Griffiths

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.